The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The company plans to expand its portfolio in regulated markets aggressively
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
FUJIFILM will distribute iSWAB bio sampling technologies in Japan
Lilly will continue to maintain its existing operating model for the remaining portfolio of products
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
The acquisition complements and strengthens Merck’s cardiovascular pipeline
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies
Subscribe To Our Newsletter & Stay Updated
